Pharmafile Logo

Kathy O’Connell joins Research Partnership as Senior Vice President, Business Development

April 29, 2024 | Insights, US, healthcare, market research 

- PMLiVE

Kathy has been working in the pharmaceutical market research industry for over 25 years. She has a diverse business background, with in-depth experience in progressively responsible sales, business development and client management. Throughout her career, Kathy has worked extensively at guiding her clients to identify the optimal research approach to address the business issue at hand. In Kathy’s most recent position as Senior Vice President, Business Development at ThinkGen, she was responsible for implementing the business development and marketing strategy and overseeing all client outreach.

In 2023, Kathy was honored with the Healthcare Businesswomen’s Association (HBA) Luminary Award which recognizes professionals who have made a significant impact on the healthcare industry and have a proven track record of helping advance careers of other women. Kathy also volunteered as a HBA mentor as part of the HBA Mentoring Program.

In this pivotal role at Research Partnership, Kathy will be working with our Commercial Team to identify new business opportunities, nurture existing partnerships and enhance our US based presence in the market.  

US President, Sue Wild commented “I am delighted to welcome Kathy to the team, she has extensive experience and will be instrumental in nurturing our client relationships in the US market. I look forward to collaborating with Kathy to strengthen our offerings in delivering the best possible insights for our valued clients”.

Find out more. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Interactive infographic: LATAM

An overview of the six most-commonly researched, largest pharma markets in Latin America

Immuno-oncology: The market opportunity for PD-1/PD-L1s

Immuno-oncology is the new frontier in cancer treatment. Using the body’s own immune system to treat cancer, new therapies are producing impressive survival benefits, with reduced side effects. Of these therapies,...

Case Study: Using ‘Journey to the Future’ projective techniques to understand evolving customer expectations

Our client was developing a portfolio of innovative treatments and was in the process of recruiting a sales force to support the promotion of this portfolio. Research was required to...

Pegasus scoops five ‘Consultancy’ wins, making 2016 a stellar year for the health comms consultancy

Pegasus, an Ashfield company, part of UDG Healthcare plc, last night scooped its fifth ‘consultancy’ award of the year at the PRCA Awards in London’s Park Lane where it secured...

Free Thinking – US Presidential Election: The legacy of the Affordable Care Act and the future for healthcare

Our latest Free Thinking white paper explores the legacy of the Affordable Care Act and the future for healthcare

Pegasus crowned PR Week’s Specialist Consultancy of the Year, making a hat-trick of Consultancy wins in 2016!

Pegasus, an Ashfield company, part of UDG Healthcare plc, is delighted to have been crowned Specialist Consultancy of the Year at this week’s prestigious PR Week Awards. The accolade tops...

Therapy Watch market snapshots

Therapy Watch is a ‘real-time’ syndicated market tracking tool that provides marketing teams, brand managers and market researchers with strategic and tactical market information. Run entirely online to ensure speed,...

Case Study: Private market opportunity for a travel vaccine

Our client needed exploratory research to determine the global opportunity for a new travel vaccine in the private market. It was crucial to determine:Which markets had the highest potential to...

Infographic: Conference Live

Conference Live gives you real-time insights, utilising the multimedia functionality of the smartphone in an innovative mobile app methodology. We conduct mobile conference research amongst physicians attending conferences, giving our clients...

Blog: The Cost of Counterfeits

The sale of counterfeit drugs is growing at twice the rate of legitimate pharmaceuticals and pharma companies stand to lose more than just profits from the fallout of counterfeit identification.